Aspirin, NSAIDs, and risk of prostate cancer: Results from the REDUCE study

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 756-762

  Vidal, Adriana C ^a,b   Howard, Lauren E ^a,b   Moreira, Daniel M ^c   Castro Santamaria, Ramiro ^d   Andriole, Gerald L ^e   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d GLAXOSMITHKLINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DUTASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY MASS; CANCER GRADING; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DIGITAL RECTAL EXAMINATION; DOUBLE BLIND PROCEDURE; DRUG USE; GLEASON SCORE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; POPULATION RESEARCH; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SMOKING; TREATMENT DURATION; CLINICAL TRIAL; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOUBLE-BLIND METHOD; DUTASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84923172081     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2235     Document Type: Article

References (36)

1. Li S, Liu Y, Zeng Z, Peng Q, Li R, Xie L, et al. Association between nonsteroidal anti-in flammatory drug use and melanoma risk: a meta-analysis of 13 studies. Cancer Causes Control 2013;24:1505-16.
2. Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012;131:581-7.
3. Xu J, Yin Z, Gao W, Liu L, Wang R, Huang P, et al. Meta-analysis on the association between nonsteroidal anti-infl ammatory drug use and lung cancer risk. Clin Lung Cancer 2012;13:44-51.
4. Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010;127:1680-91.
5. Jafari S, Etminan M, Afshar K. Nonsteroidal anti-in flammatory drugs and prostate cancer: a systematic review of the literature andmeta-analysis. Can Urol Assoc J 2009;3:323-30.
6. Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, et al. Effect of aspirin and other non-steroidal anti-in fl ammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med 2014;12:55.
7. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
8. Murad AS, DownL, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, et al. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer 2011;128:1442-8.
9. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013;49:938-45.
10. Nelson JE, Harris RE. Inverse association of prostate cancer and nonsteroidal anti-infl ammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000;7:169-70.
11. Garcia Rodriguez LA, Gonzalez-Perez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004;13:649-53.
12. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-infl ammatory drugs and prostate cancer occurrence. Cancer J (Sudbury, Mass) 2006;12:130-5.
13. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 2006;164:984-9.
14. Chang SL, Harshman LC, Presti JC Jr. Impact of common medications on serum total prostate-specifi c antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010;28:3951-7.
15. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
16. Sabichi AL, Lippman SM. COX-2 inhibitors and other nonsteroidal antiinflammatory drugs in genitourinary cancer. Semin Oncol 2004;31: 36-44.
17. Huang TB, Yan Y, Guo ZF, Zhang XL, Liu H, Geng J, et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014;46:1715-28.
18. Bosetti C, Rosato V, Gallus S, La Vecchia C. Aspirin and urologic cancer risk: an update. Nat Rev Urol 2012;9:102-10.
19. Botting RM. Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology. Pharmacol Rep 2010;62:518-25.
20. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
21. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8.
22. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, et al. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 2000;86:736-41.
23. Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign andmalignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994;57:176-80.
24. Tjandrawinata RR, Hughes-Fulford M. Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. Adv Exp Med Biol 1997;407:163-70.
25. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxy-genase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-8.
26. Badawi AF. The role of prostaglandin synthesis in prostate cancer. BJU Int 2000;85:451-62.
27. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-31.
28. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980;124:2682-7.
29. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301-9.
30. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998;77:511-5.
31. Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006;17: 251-6.
32. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 2010; 19:3185-8.
33. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011;6:e16412.
34. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal antiinflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-80.
35. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C. Aspirin and the risk of prostate cancer. Eur J Cancer Prev 2006;15:43-5.
36. Thomas JA 2nd, Gerber L, Banez LL, Moreira DM, Rittmaster RS, Andriole GL, et al. Prostate cancer risk inmenwith baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev 2012;21:576-81.